A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Main Inclusion Criteria:

- Patient must have histologically confirmed, advanced (FIGO Stage III or IV) high-grade
predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary
peritoneal cancer who have completed first line platinum based chemotherapy
(neoadjuvant or adjuvant)

- Patient must have clinical complete response or partial response following completion
of chemotherapy course.

- All Stage IV patients are eligible, irrespective of residual disease, after primary or
interval debulking. Stage III patients are required to have visible residual disease
after primary surgery. Patients with inoperable Stage III and IV disease are eligible

- Patient must agree to undergo central tumor HRD testing

- Patients of childbearing potential must have negative pregnancy serum test within 72
hours of being dosed

- Patient must be randomized within 12 weeks of the first day of the last cycle of
chemotherapy

Main Exclusion Criteria:

- Patient has mucinous or clear cell subtypes of epithelial ovarian cancer,
carcinosarcoma or undifferentiated ovarian cancer

- Patient has undergone more than 2 debulking surgeries

- Patient is to receive bevacizumab as maintenance treatment

- Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving
study treatment and for 180 days after the last dose of study treatment

- Patient has had prior treatment with a known PARP inhibitor

- Patient has been diagnosed and/or treated for any invasive cancer (other than study
disease) less than 5 years prior to study enrollment.